At the close on Thursday, shares in Marlborough, Massachusetts headquartered Hologic Inc. climbed 0.48%, ending the day at $40.08. The stock recorded a trading volume of 1.38 million shares. The Company's shares have advanced 2.82% in the last one month, 5.09% in the previous three months, and 3.59% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 4.30% and 8.89%, respectively. Moreover, shares of Hologic, which develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the US, Europe, the Asia/Pacific, and internationally, have a Relative Strength Index (RSI) of 59.87.
On December 14th, 2016, Grifols announced that it has entered into an agreement to acquire the NAT (Nucleic Acid Testing) donor screening unit from Hologic for a purchase price of $1.85 billion (EUR 1.75 billion). HOLX complete research report is just a click away and free at:
St. Jude Medical
Shares in St. Paul, Minnesota headquartered St. Jude Medical Inc. ended the day 0.03% higher at $79.83 with a total trading volume of 1.22 million shares. The stock has gained 0.16% in the past month, 1.10% over the previous three months, and 31.02% on an YTD basis. The Company's shares are trading above their 50-day and 20-day moving averages by 0.63% and 5.66%, respectively. Furthermore, shares of St. Jude Medical, which together with its subsidiaries, develops, manufactures, and distributes cardiovascular medical devices for cardiac rhythm management, cardiovascular, and atrial fibrillation therapy areas worldwide, have an RSI of 53.74.
On December 15th, 2016, St. Jude Medical announced FDA clearance of its EnSite Precision™ cardiac mapping system and Advisor™ FL Circular Mapping Catheter, Sensor Enabled™. The new EnSite Precision cardiac mapping system is the latest addition to the Company's electrophysiology portfolio, and is designed to provide automation, flexibility and precision in cardiac mapping during the treatment of patients with abnormal heart rhythms (cardiac arrhythmias). The complimentary report on STJ can be downloaded at:
On Thursday, shares in Irvine, California headquartered Edwards Lifesciences Corp. finished 1.08% higher at $93.71 with a total trading volume of 1.33 million shares. The stock has advanced 11.69% in the last one month and 18.65% on an YTD basis. The Company's shares are trading above their 50-day moving average by 1.21%. Additionally, shares of Edwards Lifesciences, which provides products and technologies to treat structural heart disease and critically ill patients worldwide, have an RSI of 61.61.
On December 8th, 2016, Edwards Lifesciences announced that it expects underlying sales growth of 10 to 14%, or $3.0 billion to $3.4 billion for FY17. Additionally, the Company expects diluted adjusted earnings per share of $3.30 to $3.45. This includes estimated net dilution of $0.10 per share from the pending acquisition of Valtech Cardio, and an estimated $0.08 to $0.13 per share benefit from the accounting change related to stock-based compensation. The Company also expects free cash flow of $575 million to $650 million, with all guidance excluding special items. Sign up for your complimentary research report on EW at:
Warsaw, Indiana headquartered Zimmer Biomet Holdings Inc.'s shares recorded a trading volume of 683,275 shares at the end of yesterday's session. The stock closed the day 0.43% higher at $103.50. The Company's shares have advanced 0.33% in the last one month and 1.76% since the start of this year. The stock is trading below its 50-day moving average by 2.68%. Additionally, shares of Zimmer Biomet Holdings, which together with its subsidiaries, provides musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia/Pacific, have an RSI of 51.84.
On December 13th, 2016, Zimmer Biomet announced the launch of PrimaGen Advanced Allograft, an autograft substitute, containing the same bone healing elements as autograft, but without the risks associated with donor site morbidity or harvest site complications. The Company stated that PrimaGen Advanced Allograft offers a combination of demineralized cortical bone fibers with verified osteoinductivity and cancellous bone, providing a trabecular structure for natural bony in-growth with optimal handling and delivery characteristics. Get free access to your research report on ZBH at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA